Avanos Medical reports Q1 results and holds annual meeting; all proposals approved

AVANOS MEDICAL, INC.

Q1 2023 earnings released May 3, 2023; no financial figures provided in the filing.
Annual meeting held Apr 27, 2023; 94.23% of shares represented (43,916,111 shares).
All six director nominees elected; Dr. Julie Shimer received lowest support (35.5M for, 6.2M withheld).
Delaware auditor ratified (43.5M for, 0.27M against); advisory say-on-pay approved (38.96M for, 2.59M against).
LTIP amended to increase authorized shares by 1.25M (39.96M for, 1.59M against).

item 2.02 item 5.07 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.81

AVANOS MEDICAL, INC. reported financial results for the three months ended March 31, 2023.

Period: the three months ended March 31, 2023
Result: reported results

Exact text from the filing

Avanos Medical, Inc. (the “Company”) announced its results of operations for the three months ended March 31, 2023 in a press release dated May 3, 2023.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

AVANOS MEDICAL, INC. shareholders approved Approve an amendment to the Company’s 2021 Long Term Incentive Plan to increase the number of shares reserved for issuance at the 2023-04-27 meeting.

Proposal: equity plan
Outcome: passed
Meeting: 2023-04-27

Exact text from the filing

The votes cast on Proposal No. 4 were as follows: For Against Abstain Broker non-votes Amendment of the 2021 Long Term Incentive Plan 39,961,025 1,585,386 112,920 2,256,780

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

AVANOS MEDICAL, INC. shareholders approved Ratify the appointment of Deloitte & Touche LLP as the Company’s independent auditors for 2023 at the 2023-04-27 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-04-27

Exact text from the filing

The votes cast on Proposal No. 2 were as follows: For Against Abstain Appointment of Deloitte & Touche LLP 43,502,269 268,752 145,090

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

AVANOS MEDICAL, INC. shareholders approved Approval, on an advisory basis, of the compensation of the Company’s named executive officers at the 2023-04-27 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2023-04-27

Exact text from the filing

The votes cast on Proposal No. 3 were as follows: For Against Abstain Broker non-votes Approval of NEO compensation 38,956,746 2,593,580 109,005 2,256,780

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

AVANOS MEDICAL, INC. shareholders approved Election of directors at the 2023-04-27 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-04-27

Exact text from the filing

The votes cast on Proposal No. 1 were as follows: Director For Withhold Broker non-votes Gary D. Blackford 40,939,693 719,638 2,256,780 John P. Byrnes 41,020,988 638,343 2,256,780 Dr. Lisa Egbuonu-Davis 41,187,183 472,148 2,256,780 Patrick J. O’Leary 41,327,319 332,012 2,256,780 Dr. Julie Shimer 35,455,820 6,203,511 2,256,780 Joseph F. Woody 41,422,567 236,764 2,256,780

View on SEC.gov

Browse all earnings releases →

AVANOS MEDICAL, INC. filing history →

Source: SEC EDGAR

accession 0001606498-23-000039

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.